Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate is a prodrug that is taken up by skin cells and converted into protoporphyrin IX. When the treated area is exposed to visible light, protoporphyrin IX generates reactive oxygen species that cause localized oxidative damage, selectively killing dysplastic or cancerous cells while sparing normal tissue.

The exact amount of Metvix to apply and the illumination protocol are determined by the prescribing clinician based on lesion size, location, and patient factors. The prescriber will provide specific instructions on how much cream to spread, the incubation time, and the light dose required.

Safety of Metvix in pregnancy and lactation has not been established. Because the drug is a photosensitizer with potential systemic effects, it is generally avoided in pregnant or breastfeeding women unless the potential benefit outweighs the unknown risk, as decided by the treating physician.

To request Metvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to Metvix is aminolevulinic acid (ALA) based creams such as Ameluz. Both are photosensitizers used in photodynamic therapy, but methyl aminolevulinate typically provides deeper penetration and may require a shorter incubation period, while ALA formulations often need longer exposure times. Choice depends on lesion characteristics and physician preference.

Metvix should be stored at room temperature, below 25 °C, in its original packaging. Keep the cream away from direct light and moisture to maintain stability. Do not freeze the product, and ensure the container is tightly closed when not in use.

Metvix is applied topically to the cleaned skin lesion in a thin, even layer. After a prescribed incubation period (usually a few hours), the area is illuminated with a calibrated visible‑light source for a defined duration. The procedure is performed by a qualified healthcare professional in a clinical setting.

The most serious risks include severe photosensitivity reactions that can affect untreated skin, allergic dermatitis, secondary bacterial infection of the treated site, and persistent scarring or hyperpigmentation. Patients should be monitored closely for these events, and any severe reaction should prompt immediate medical evaluation.

Metvix should not be used in individuals with known hypersensitivity to methyl aminolevulinate or any component of the formulation, in patients with active skin infections at the treatment site, or in pregnant or breastfeeding women unless the prescriber determines that the benefits outweigh the potential risks.